Advertisement

Obstetric Drugs in the Management of Cardiovascular Disease

  • Catherine ElliottEmail author
Chapter
  • 1.2k Downloads
Part of the Current Cardiovascular Therapy book series (CCT)

Abstract

Cardiac Disease complicates 0.6 % of pregnancies in South Africa (Sliwa et al. 2010). The term cardiac disease encompasses all possible heart disease from structural congenital lesions, to functional abnormalities and acquired valve lesions. When women suffering from cardiac disease conceive, the physiological haemodynamic changes in pregnancy as well as potential obstetric complications can result in cardiac deterioration. Medications used in the management of both routine general obstetrics and in the case of obstetric emergencies may adversely affect the heart function. Knowledge of the mechanisms of action of obstetric medications and potential side effects is vital when managing pregnant women with heart disease.

Keywords

Preterm Labour Postpartum Haemorrhage Uterine Contraction Ergot Alkaloid Magnesium Sulphate 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. Aflaifel N, Weeks AD. Active management of the third stage of labour. BMJ. 2012;345:e4546.PubMedCrossRefGoogle Scholar
  2. Caughey AB, Parer JT. Tocolysis with beta-adrenergic receptor agonists. Semin Perinatol. 2001;25:248–55.PubMedCrossRefGoogle Scholar
  3. Crowther CA, Hiller JE, Doyle LW, Haslam RR, Australasian Collaborative Trial of Magnesium Sulphate Collaborative Group. Effect of magnesium sulfate given for neuroprotection before preterm birth: a randomized controlled trial. JAMA. 2003;290:2669–76.PubMedCrossRefGoogle Scholar
  4. David M. Nifedipine pharmacokinetics are influenced by the CYP. Am J Perinatol. 2013;30:275–82.Google Scholar
  5. Doyle L. Magnesium sulphate for women at risk of preterm birth for neuroprotection of the fetus. Cochrane Database Syst Rev. 2010;(3):CD004661. http://www.thecochranelibrary.com.
  6. Dyer RA, van Dyk D, Dresner A. The use of uterotonic drugs during caesarean section. Int J Obstet Anesth. 2010;19:313–9.PubMedCrossRefGoogle Scholar
  7. Elliott C. Complications of anticoagulation on the management of pregnant women with mechanical heart valves. MMED, University of Cape Town, 2012.Google Scholar
  8. Gibbon C. South African medical formulary. 7th ed. Cape Town: South African Medical Association; 2005.Google Scholar
  9. Gohil T. A study to compare the efficacy of misoprostol, oxytocin, methyl-ergometrine and ergometrin-oxytocin in reducing blood loss in active management of 3rd stage of labour. J Obstet Gynaecol India. 2001;61:408–12.CrossRefGoogle Scholar
  10. Goodwin TM, Millar L, North L, Abrams LS, Weglein RC, Holland ML. The pharmacokinetics of the oxytocin antagonist atosiban in pregnant women with preterm uterine contractions. Am J Obstet Gynecol. 1995;173:913–7.PubMedCrossRefGoogle Scholar
  11. Kashanian M, Akbarian AR, Soltanzadeh M. Atosiban and nifedipin for the treatment of preterm labor. Int J Gynaecol Obstet. 2005;91:10–4.PubMedCrossRefGoogle Scholar
  12. Moutquin JM, Sherman D, Cohen H, Mohide PT, Hochner-Celnikier D, Fejgin M, Liston RM, Dansereau J, Mazor M, Shalev E, Boucher M, Glezerman M, Zimmer EZ, Rabinovici J. Double-blind, randomized, controlled trial of atosiban and ritodrine in the treatment of preterm labor: a multicenter effectiveness and safety study. Am J Obstet Gynecol. 2000;182:1191–9.PubMedCrossRefGoogle Scholar
  13. Nelson-Piercy C. Medical disorders of pregnancy. 4th ed. New York: Informa Healthcare; 2002.Google Scholar
  14. Powrie R. De Swiet’s medical disorders in obstetric practice. 5th ed. Chichester: Wiley-Blackwell; 2010.CrossRefGoogle Scholar
  15. Ramsey PS, Rouse DJ. Magnesium sulfate as a tocolytic agent. Semin Perinatol. 2001;25:236–47.PubMedCrossRefGoogle Scholar
  16. Romero R, Sibai BM, Sanchez-Ramos L, Valenzuela GJ, Veille JC, Tabor B, Perry KG, Varner M, Goodwin TM, Lane R, Smith J, Shangold G, Creasy GW. An oxytocin receptor antagonist (atosiban) in the treatment of preterm labor: a randomized, double-blind, placebo-controlled trial with tocolytic rescue. Am J Obstet Gynecol. 2000;182:1173–83.PubMedCrossRefGoogle Scholar
  17. Roos C, Spaanderman ME, Schuit E, Bloemenkamp KW, Bolte AC, Cornette J, Duvekot JJ, van Eyck J, Franssen MT, de Groot CJ, Kok JH, Kwee A, Merien A, Nij Bijvank B, Opmeer BC, Oudijk MA, van Pampus MG, Papatsonis DN, Porath MM, Scheepers HC, Scherjon SA, Sollie KM, Vijgen SM, Willekes C, Mol BW, van der Post JA, Lotgering FK, APOSTEL-II Study Group. Effect of maintenance tocolysis with nifedipine in threatened preterm labor on perinatal outcomes: a randomized controlled trial. JAMA. 2013;309:41–7.PubMedCrossRefGoogle Scholar
  18. Rouse DJ, Hirtz DG, Thom E, Varner MW, Spong CY, Mercer BM, Iams JD, Wapner RJ, Sorokin Y, Alexander JM, Harper M, Thorp Jr JM, Ramin SM, Malone FD, Carpenter M, Miodovnik M, Moawad A, O’Sullivan MJ, Peaceman AM, Hankins GD, Langer O, Caritis SN, Roberts JM, Eunice Kennedy Shriver, N. M.-F. M. U. N. A randomized, controlled trial of magnesium sulfate for the prevention of cerebral palsy. N Engl J Med. 2008;359:895–905.Google Scholar
  19. Royal College of Obstetrics and Gynaecology. Tocolysis for women in preterm labour. London: Royal College of Obstetrics and Gynaecology; 2011. http://www.rcog.org.uk/womens-health/clinical-guidance/tocolytic-drugs-women-preterm-labour-green-top-1b.
  20. Sliwa K, Hilfiker-Kleiner D, Petrie M, Mebazaa A, Pieske B, Buchmann E, Regitz-Zagrosek V, Schaufelberger M, Tavazzi B, van Veldhuisen DJ, Watkins H, Shah AJ, Seferovic PM, Elkayam U, Pankuweit S, Papp Z, Mouquet F, McMurray J. Current state of knowledge on aetiology, diagnosis, management, and therapy of peripartum cardiomyopathy: a position statement from the Heart Failure Association of the European Society of Cardiology Working Group on Peripartum Cardiomyopathy. Eur Heart J. 2010;12:767–78.CrossRefGoogle Scholar
  21. Sorensen TK, Easterling TR, Carlson KL, Brateng DA, Benedetti TJ. The maternal hemodynamic effect of indomethacin in normal pregnancy. Obstet Gynecol. 1992;79:661–3.PubMedGoogle Scholar
  22. The Canadian Preterm Labor Investigators Group. Treatment of preterm labor with the beta-adrenergic agonist ritodrine. N Engl J Med. 1992;327:308–12.CrossRefGoogle Scholar
  23. Valenzuela GJ, Craig J, Bernhardt MD, Holland ML. Placental passage of the oxytocin antagonist atosiban. Am J Obstet Gynecol. 1995;172:1304–6.PubMedCrossRefGoogle Scholar
  24. Valenzuela GJ, Sanchez-Ramos L, Romero R, Silver HM, Koltun WD, Millar L, Hobbins J, Rayburn W, Shangold G, Wang J, Smith J, Creasy GW. Maintenance treatment of preterm labor with the oxytocin antagonist atosiban. The Atosiban PTL-098 Study Group. Am J Obstet Gynecol. 2000;182:1184–90.PubMedCrossRefGoogle Scholar
  25. Vermillion ST, Landen CN. Prostaglandin inhibitors as tocolytic agents. Semin Perinatol. 2001;25:256–62.PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag London 2014

Authors and Affiliations

  1. 1.Department of Obstetrics and GynaecologyGroote Schuur HospitalCape TownSouth Africa

Personalised recommendations